Protective efficacy of virus-like particles for bluetongue disease
- PMID: 1311487
- DOI: 10.1016/0264-410x(92)90415-g
Protective efficacy of virus-like particles for bluetongue disease
Abstract
Bluetongue virus-like particles (VLPs) derived from multiple baculovirus expression vectors have been administered in the presence of various adjuvants to sheep, a vertebrate host susceptible to the virus, and the neutralizing antibody responses are measured. Vaccinated sheep are challenged after 4 months of inoculation, and clinical reaction indices and viraemia determined. The results indicate that these multiprotein virus-like particles lacking the genetic material are highly immunogenic and as little as 10 micrograms of VLPs in conjunction with appropriate adjuvant elicit an immune response which protects against infectious virus challenge. The formation of virus-like particles using this new technology offers a novel approach in vaccinology.
Similar articles
-
Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.Vaccine. 2012 Mar 9;30(12):2131-9. doi: 10.1016/j.vaccine.2012.01.042. Epub 2012 Jan 26. Vaccine. 2012. PMID: 22285887
-
From genes to complex structures of bluetongue virus and their efficacy as vaccines.Vet Microbiol. 1992 Nov;33(1-4):155-68. doi: 10.1016/0378-1135(92)90043-s. Vet Microbiol. 1992. PMID: 1336237
-
Recombinant virus vaccine for bluetongue disease in sheep.J Virol. 1990 May;64(5):1998-2003. doi: 10.1128/JVI.64.5.1998-2003.1990. J Virol. 1990. PMID: 2157868 Free PMC article.
-
Nature and duration of protective immunity to bluetongue virus infection.Dev Biol (Basel). 2003;114:169-83. Dev Biol (Basel). 2003. PMID: 14677687 Review.
-
Genetically engineered multi-component virus-like particles as veterinary vaccines.Immunol Cell Biol. 1993 Oct;71 ( Pt 5):381-9. doi: 10.1038/icb.1993.44. Immunol Cell Biol. 1993. PMID: 8270267 Review.
Cited by
-
Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system.FEBS Lett. 2004 Oct 8;576(1-2):174-8. doi: 10.1016/j.febslet.2004.09.009. FEBS Lett. 2004. PMID: 15474033 Free PMC article.
-
Soluble expression and purification of Bluetongue Virus Type 1 (BTV1) structure protein VP2 in Escherichia coli and its immunogenicity in mice.PeerJ. 2021 Jan 4;9:e10543. doi: 10.7717/peerj.10543. eCollection 2021. PeerJ. 2021. PMID: 33505791 Free PMC article.
-
Oncolytic bluetongue viruses: promise, progress, and perspectives.Front Microbiol. 2011 Mar 16;2:46. doi: 10.3389/fmicb.2011.00046. eCollection 2011. Front Microbiol. 2011. PMID: 21747785 Free PMC article.
-
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.Vaccines (Basel). 2022 Jul 14;10(7):1124. doi: 10.3390/vaccines10071124. Vaccines (Basel). 2022. PMID: 35891288 Free PMC article. Review.
-
A review of experimental infections with bluetongue virus in the mammalian host.Virus Res. 2014 Mar;182:21-34. doi: 10.1016/j.virusres.2013.12.044. Epub 2014 Jan 24. Virus Res. 2014. PMID: 24462840 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources